Chen Wei, Xie Dan, Luo Jun-hang, Wang Chang-xi, Tao Yu, Zheng Ke-li, Mei Hua
Department of Urology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Zhonghua Wai Ke Za Zhi. 2006 Jan 15;44(2):111-4.
To investigate the expression of clusterin protein in bladder transitional cell carcinoma (BTCC) and it's association with tumor cell proliferation and apoptosis.
A tissue microarray (TMA) containing 87 informative cases of BTCCs was constructed firstly. The methods of immunohistochemistry and terminal deoxynucleotidyl transferase-mediated nick end-labeling were then used to examine the expression of clusterin and Ki-67 protein and the status of cell apoptosis in BTCC, respectively, and the correlations between different markers and the clusterin expression associated with patients' clinico-pathological features were evaluated.
In TMA of 87 BTCCs, 37 (43%) cases were observed overexpression of clusterin. A significant association of clusterin expression with BTCC's pathological grade, as well as with tumors clinical stage was observed (P < 0.01), where the frequency of overexpression of clusterin in poor differentiated BTCCs (G(3), 71%) and tumors in more advanced stage (T(2-4), 62%) was significantly higher than that in well differentiated BTCCs (G(1-2), 29%) and tumors in early stage (T(a-1), 28%). In addition, a significant correlation between clusterin expression and tumors apoptotic index (AI) was evaluated (P < 0.01), in which 57% of BTCCs with overexpression of clusterin were observed a lower AI, while 72% of tumors with normal expression of this protein showed a higher AI, but no correlation between clusterin and Ki-67 expression.
The overexpression of clusterin is associated positively with BTCC's malignant clinical phenotypes including tumor's differentiation and invasive depth, and it is correlated inversely with AI of tumor cells.
探讨簇集素蛋白在膀胱移行细胞癌（BTCC）中的表达及其与肿瘤细胞增殖和凋亡的关系。
首先构建包含87例信息完整的BTCC病例的组织芯片（TMA）。然后分别采用免疫组织化学和末端脱氧核苷酸转移酶介导的缺口末端标记法检测BTCC中簇集素和Ki-67蛋白的表达以及细胞凋亡情况，并评估不同标志物与簇集素表达之间的相关性以及与患者临床病理特征的关系。
在87例BTCC的TMA中，37例（43%）观察到簇集素过表达。观察到簇集素表达与BTCC的病理分级以及临床分期显著相关（P < 0.01），其中低分化BTCC（G(3)，71%）和晚期肿瘤（T(2 - 4)，62%）中簇集素过表达的频率显著高于高分化BTCC（G(1 - 2)，29%）和早期肿瘤（T(a - 1)，28%）。此外，评估了簇集素表达与肿瘤凋亡指数（AI）之间的显著相关性（P < 0.01），其中57%簇集素过表达的BTCC观察到较低的AI，而72%该蛋白表达正常的肿瘤显示较高的AI，但簇集素与Ki-67表达之间无相关性。
簇集素的过表达与BTCC的恶性临床表型包括肿瘤分化和浸润深度呈正相关，与肿瘤细胞的AI呈负相关。
